Immune checkpoint inhibitors in advanced oral cancer

A tétel rövid nézete
dc.contributor.advisorMegyeri, Attila
dc.contributor.advisordeptDepartment of Pharmacology and Pharmacotherapyhu_HU
dc.contributor.authorAmid, Dana
dc.contributor.departmentDE--Fogorvostudományi Karhu_HU
dc.date.accessioned2021-05-14T06:03:41Z
dc.date.available2021-05-14T06:03:41Z
dc.date.created2021-03-05
dc.description.abstractOral cancer is the sixth most common type of cancer worldwide, especially oral squamous cell carcinoma. Most intraoral tumors are treated by a combination of surgery and radiotherapy. For those cases where progression is still observed after the conventional treatment options, other newer options became available, such as immune checkpoint inhibitors. Those drugs have shown great success as a treatment approach for head and neck cancer, and after highly positive outcome in clinical trials, both nivolumab and pembrolizumab, PD-1 blockers, were approved by the FDA as a treatment for head and neck cancer.hu_HU
dc.description.coursefogorvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeMSc/MAhu_HU
dc.format.extent40hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/309583
dc.language.isoenhu_HU
dc.subjectoral cancerhu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titleImmune checkpoint inhibitors in advanced oral cancerhu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Dentistry)